Erbe Elektromedizin inaugurates new competence center for medical instruments in Rangendingen, Germany, and expands its capacities for customers all over the world
6.6.2024 09:11:00 EEST | Business Wire | Press release
Erbe Elektromedizin has inaugurated a new production and development building in Rangendingen, Germany, after three years of construction. At 90 million euros, the new 25,000 m² building is the largest single investment in the company's history and represents another important part in the global network. The building combines production, product development, logistics and administration. Erbe will now develop and produce medical technology instruments for customers all over the world at its Rangendingen site near Tübingen. With the new building, the company is expanding its capacities and is even better equipped to deal with the consequences of global crises. The building is a pioneering achievement in terms of ecological, social and economic sustainability. Among the guests on May 3 were the Chairman of the Free Democratic Party, Christian Lindner, and the Minister of Economic Affairs of Baden-Württemberg, Dr. Nicole Hoffmeister-Kraut.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240603323747/en/
New Erbe production and development building in Rangendingen, Germany (Photo: Business Wire)
On May 3rd, Erbe opened its newest plant in Rangendingen near Tübingen. The new competence center is dedicated to the development and production of medical instruments for our customers around the world. Erbe is expanding its capacities in order to be even more robust in case of supply bottlenecks resulting from international crisis. In this manner, Erbe ensures uninterrupted business operations. This enables us to consistently deliver the highest quality to our customers worldwide.
An important aspect for ensuring continuous economic success is the concept of sustainability. For Erbe, “Made in Germany” means the future of Germany as a business location in harmony with innovative medical technology and a pioneering role for sustainable, responsible entrepreneurship.
“Erbe is a symbol of what makes our country strong,” explained Christian Lindner, Chairman of the Free Democratic Party (FDP) in his speech. He commended the location decision and emphasized the importance of supporting family businesses, stating, “They are the ones who create prosperity.”
“We have set the course for a new standard with our construction project in Rangendingen,” explains Marcus Felstead, Chief Commercial Officer.
“Because tomorrow's customers will place even more value on sustainability than we already do today. We want to meet these demands.”
Both planning and construction of the building had this as a goal. In order to realize ecological, social and economic aspects of the corporate strategy and combine them in an industrial building, Erbe relied on the use of high-quality ecological building materials for the supporting structure and the façade, the use of renewable energy technology and the implementation of numerous measures for an optimal working environment for employees.
A highlight of the building is one of the largest photovoltaic systems in the region. The 2,800 solar panels on the roof with an output of 1 MW produce 610,000 kWh of electricity per year and cover a third of the energy required for operations. This is supplemented by a combined heat and power plant powered by CO2-neutral biogas.
“We implemented the most demanding standards for energy efficiency and achieved KfW Efficiency Level 40 Plus,” explains Christian O. Erbe. “This means, that our building is more than twice as energy efficient compared to conventional structures, making it a leader in the field of sustainable industrial building.”
Up to 500 employees will be working on site. They benefit from a modern, employee-centered working environment. The company's social responsibility also includes a distinctive health concept for employees, including company medical care, health weeks and financial support for sporting activities. There are exercise islands in the building for fitness, a room for yoga, leisure activities and relaxation rooms.
About Erbe Elektromedizin
Erbe Elektromedizin develops, manufactures, and distributes surgical instruments and devices worldwide, while providing services for professional use of these products in a diverse range of medical disciplines. Surgeons, OP teams and patients around the world rely on Erbe medical technology. The surgical instruments and devices find use in almost all specialist areas. They are based on electrosurgery combined with other Erbe technologies. Hybrid solutions enable us to provide new, innovative applications in medicine.
Fields of activity
- Imaging
- Endoscopy
- Electrosurgery
- Plasma surgery
- Thermofusion
- Hydrosurgery
- Cryosurgery
An international network
- 18 international sales and service units
- 4 production sites
- Erbe is active in 110 international markets.
The Erbe workforce
- Over 1,900 employees worldwide
- Some 1,000 of them in Germany
Erbe Elektromedizin GmbH
Waldhoernlestr. 17,
72072 Tübingen
www.erbe-med.com
info@erbe-med.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240603323747/en/
Contact information
David Malecki
Tel +49 7071 755-316
david.malecki@erbe-med.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers17.7.2026 20:10:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced that it will highlight data from several programs in its oncology portfolio in six presentations at the European Society of Medical Oncology (ESMO) Congress 2026, being held October 23 - 27, 2026, in Madrid. “The data at ESMO will further illustrate Incyte’s commitment to advancing innovation for patients with cancer,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "Among the presentations are important updates from our KRAS G12D inhibitor in advanced pancreatic cancer and colorectal cancer, our TGFβR2×PD-1 bispecific antibody in microsatellite stable colorectal cancer and our CDK2 inhibitor in recurrent epithelial ovarian cancer – investigational approaches that reflect our focus on areas where there is significant need for novel therapies." Details on key data presentations at ESMO include: Rapid Oral Presentations INCB161734 (KRAS G12D) Safety and Efficacy of Oral KRAS G12D Inhibitor INCB161734 as Mono
STL Expands Its Optical Connectivity Portfolio in the US with the CONCAT Solution17.7.2026 15:24:00 EEST | Press release
STL Optical Connectivity NA, LLC, (STLOC), a U.S. subsidiary of STL (Sterlite Technologies Ltd.) [NSE: STLTECH], a leading connectivity solutions provider for AI-ready digital infrastructure, today announced that it launched its new advanced FTTH solution, CONCAT, after successfully completing field trials on the networks of one of the largest telecom service providers in the United States. Following successful field validation, CONCAT is now available to digital infrastructure providers seeking faster fiber rollouts with reduced deployment complexity and labor. It enables up to 71% in labor cost savings by eliminating most field splicing through factory-assembled, pre-connectorized fiber segments that deliver plug-and-play installation. CONCAT simplifies fiber deployment by shifting critical fiber preparation and termination into a controlled manufacturing environment ensuring consistent quality, faster installation, and lower operational risk in the field. CONCAT solution is ideal fo
China's ~$900B Live-Commerce Market Now Approaches US E-Commerce Scale17.7.2026 13:30:00 EEST | Press release
The center of gravity in global retail has shifted East. The formats now driving the fastest growth in global retail (live shopping, social commerce, and delivery in minutes) were pioneered and scaled in Asia, and most Western consumers have yet to adopt them. According to NIQ (NYSE: NIQ), a leading consumer intelligence company, in its global report The Commerce Revolution: Where East Meets West, the gap between East and West is still vast. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260717253489/en/ China´s USD 900bn live shopping boom now approaches the scale of the US E-commerce The scale is already substantial. China's live-commerce market alone was worth roughly $900 billion in 2025, approaching the size of the entire US e-commerce market, according to market data cited in the report. Yet 68% of consumers in North America and 67% in Europe have never once bought a product through social media, and roughly two-thirds
Aqemia and Sanofi Expand Their Research Collaboration17.7.2026 13:30:00 EEST | Press release
Aqemia, the drug invention company combining generative AI and quantum-inspired physics to invent small molecule drugs, today announced the expansion of its multi-year research collaboration with the global pharmaceutical company, Sanofi. The expansion is marked by the nomination of a new therapeutic target and an additional payment. The collaboration, first announced in December 2023, makes Aqemia eligible to receive up to a total of $140 million in upfront and milestone payments across programs. It spans the drug discovery journey from the identification of the very first hits to the selection of a development candidate. Aqemia leverages Qemi, its proprietary physics-based generative AI platform, to design novel molecules addressing Sanofi’s targets of choice, working in close collaboration with Sanofi scientific teams. Sanofi leads wet lab research, development and commercialization. The collaboration now runs across continents, between Aqemia researchers in Paris and London and San
Ant International’s Alipay+ Connects Argentina's National QR Payment Scheme via PVS, Enabling for Cross-Border Digital Payment Nationwide at Millions of Merchants17.7.2026 13:17:00 EEST | Press release
Alipay+, a global digital payment gateway under Ant International, today announced that it will enable global travellers to make QR code payments at millions of merchants across Argentina through integration with the country's national QR payment scheme Transferencias 3.0, in partnership with PVS, a fintech company specialized in developing customized payment solutions in Latin America. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260717276406/en/ By connecting to Argentina's national QR payment scheme, Alipay+ now enables global travellers in the country to make convenient QR code payments at merchants nationwide. This service helps to enhance global travellers' travel experiences in Argentina, allowing them to pay seamlessly at restaurants, malls and tourist attractions. Using an Alipay+ partner payment app, they can now scan the national QR code displayed at all merchants to make cross-border payments across Argentina,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
